LON:GENI

GENinCode Final Earnings Results & Report

GENinCode logo
GBX 0.56 -0.04 (-6.67%)
As of 11/20/2026 11:39 AM Eastern

GENinCode reported Final earnings on June 4, 2025. The company reported EPS of -GBX 2.53.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

GENinCode EPS Results

Actual EPS
-GBX 2.53
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GENinCode Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

GENinCode Final Earnings FAQ

GENinCode (LON:GENI) reported earnings of -GBX 2.53 per share for Final. The report was announced on Wednesday, June 4, 2025.

GENinCode Earnings Headlines

Are Tesla and SpaceX Going Bankrupt?
Tesla and SpaceX shares crashed right after Democrats took the House and the Senate in the midterm election. Elon Musk backed President Trump and donated millions to Republicans, and many believe he will become a political target. Brownstone Research founder Jeff Brown has seen Musk's new technology on camera. He says he is more convinced than ever that nothing can stop the coming Elon Musk revolution.tc pixel
See More GENinCode Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GENinCode? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GENinCode and other key companies, straight to your email.

About GENinCode

GENinCode (LON:GENI) is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide. GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U. GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.

View GENinCode Profile